1151802-22-0

Basic information

• Product Name: 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-Cyclopropyl-1H-pyrazole-4-boronic acid pinacol ester;1H-Pyrazole, 1-cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;1-Cyclopropyl-4-(pinacolylboronate)-pyrazole;1-cyclopropyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-Cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1-Cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);1-cyclopropylpyrazole-4-boronic acid pinacol ester
• CAS NO: 1151802-22-0
• Molecular Formula: C₁₂H₁₉BN₂O₂
• Molecular Weight: 234
• EINECS: 1592732-453-0
• Mol File: 1151802-22-0.mol

Chemical Properties

• Boiling Point: 354.3±15.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.16±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.33±0.12(Predicted)
• CAS DataBase Reference: 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1151802-22-0)
• EPA Substance Registry System: 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1151802-22-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1151802-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a pharmaceutical compound for its potential role in cancer treatment. As an c-Met kinase inhibitor, it targets a specific protein involved in cell growth and survival, making it a promising candidate for therapeutic intervention in cancer.
Used in Cancer Research:
In the field of cancer research, 1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is utilized as a research tool to study the mechanisms of c-Met kinase in cancer cell growth and proliferation. Understanding its interactions with the target protein can lead to the development of more effective cancer therapies.
Used in Drug Development:
1-Cyclopropyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is also used in drug development as a lead compound for the creation of novel cancer treatments. Its chemical properties and potential as an c-Met kinase inhibitor make it a valuable starting point for designing new drugs that can target cancer cells more effectively.

Upstream product

• 1151802-23-1 4-bromo-1-cyclopropyl-1H-pyrazole 
• 73183-34-3 bis(pinacol)diborane 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1239363-40-6 1‐cyclopropyl‐4‐iodo‐1H‐pyrazole 
• 1151814-36-6 1-cyclopropylpyrazole 

Downstream Products

• 1161361-80-3 2-(3-chloro-5-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-N-(4-(2-methylpyridin-4-yl)phenyl)propanamide 
• 1440965-10-5 3-chloro-6-(1-cyclopropyl-1H-pyrazol-4-yl)pyridazine 

Relevant articles and documents

Synthesis of NVS-BPTF-1 and evaluation of its biological activity

BPTF (bromodomain and PHD finger containing transcription factor) is a multidomain protein that plays essential roles in transcriptional regulation, T-cell homeostasis and stem cell pluripotency. As part of the chromatin remodeling complex hNURF (nucleoso

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

FUSED HETEROAROMATIC PYRROLIDINONES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.